2 active not recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 2 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Death: new trials by email Literature Review of Death trials Research Report on Death
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gene Therapy for ACM Due to a PKP2 Pathogenic Variant LX2020 - Arrhythmogenic Cardiomyopathy, PKP2-ACM | Phase 1 / Phase 2 | Active not recruiting | Lexeo Therapeutics | 10 | 2024-02-29 | 2025-11-12 |
| A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome tividenofusp alfa - Mucopolysaccharidosis II | Phase 1 / Phase 2 | Active not recruiting | Denali Therapeutics Inc. | 47 | 2020-07-16 | 2025-08-07 |
Arrhythmogenic Right Ventricular Dysplasia (1) · Cardiomyopathies (1) · Death, Sudden, Cardiac (1) · Heart Arrest (1) · Mucopolysaccharidosis II (1) · Sudden Infant Death (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Death, Sudden (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Carbohydrate Metabolism, Inborn Errors (1) · Cardiovascular Abnormalities (1) · Cardiovascular Diseases (1) · Congenital Abnormalities (1) · Connective Tissue Diseases (1) · Genetic Diseases, Inborn (1) · Genetic Diseases, X-Linked (1) · Heart Defects, Congenital (1) · Heart Diseases (1) · Heredodegenerative Disorders, Nervous System (1)
Denali Therapeutics Inc. (1) · Lexeo Therapeutics (1)
United States (2) · Canada (1) · Netherlands (1) · United Kingdom (1)
Sam Lu, MD (1)
2019 (1), 2023 (1)